Steroid eye drop treatment (difluprednate ophthalmic emulsion) is effective in reducing refractory diabetic macular edema
- PMID: 20180131
- DOI: 10.1007/s00417-010-1316-y
Steroid eye drop treatment (difluprednate ophthalmic emulsion) is effective in reducing refractory diabetic macular edema
Abstract
Purpose: To evaluate the efficacy of treatment of refractory diabetic macular edema (DME) after vitrectomy with difluprednate ophthalmic emulsion 0.05% (Durezol(TM)), and to compare this treatment with sub-Tenon's injection of triamcinolone (STTA).
Methods: This study enrolled patients with refractory diabetic macular edema that persisted despite pars plana vitrectomy in our clinic. In all subjects, more than 3 months had passed since prior treatment. Eleven eyes in ten subjects were treated with STTA (STTA group), and 11 eyes in seven subjects were treated with difluprednate ophthalmic emulsion 0.05% (Durezol(TM), Sirion Therapeutics Inc., USA) 4 times daily for the first month and then twice daily for 2 months (eye drop group).
Results: In the eye drop group, mean VA (+/- SD) was 0.67 +/- 0.35 logMAR and mean retinal thickness was 500.6 +/- 207.7 mum at baseline. After 3 months of treatment, mean VA was 0.67 +/- 0.29 and mean retinal thickness had decreased to 341.2 +/- 194.8 mum. The mean minimum value of RT during the treatment period was 300.6 +/- 123.2 mum, and significantly lower than that at baseline (Mann-Whitney U test: P = 0.003). In the STTA group, mean VA (+/- SD) was 0.67 +/- 0.35 logMAR, and mean retinal thickness was 543.3 +/- 132.6 mum at baseline. After 3 months of treatment, mean VA was 0.49 +/- 0.67, and mean retinal thickness had decreased to 378.6 +/- 135 mum. The mean minimum value of RT during the treatment period was 349.9 +/- 113.8 mum, and significantly lower than at baseline (Mann-Whitney U test: P = 0.003). The rate of effective improvement in RT did not differ between the eye drop group (73%) and STTA group (84%) (Fisher's exact test: P = 1).
Conclusions: Comparable improvements of retinal thickness were observed in the STTA and eye drop groups. Instillation of difluprednate ophthalmic emulsion 0.05% is a safe and effective treatment that does not require surgical intervention and does not produce severe side-effects.
Similar articles
-
Treatment of diffuse diabetic macular oedema using steroid eye drops.Acta Ophthalmol. 2012 Nov;90(7):628-32. doi: 10.1111/j.1755-3768.2010.02066.x. Epub 2011 Jan 14. Acta Ophthalmol. 2012. PMID: 21232079
-
Efficacy and safety of topical difluprednate in persistent diabetic macular edema.Int Ophthalmol. 2016 Jun;36(3):335-40. doi: 10.1007/s10792-015-0121-3. Epub 2015 Aug 22. Int Ophthalmol. 2016. PMID: 26296375
-
Trans-Tenon's retrobulbar triamcinolone acetonide infusion for refractory diabetic macular edema after vitrectomy.Graefes Arch Clin Exp Ophthalmol. 2005 Dec;243(12):1247-52. doi: 10.1007/s00417-005-0045-0. Epub 2005 Jul 15. Graefes Arch Clin Exp Ophthalmol. 2005. PMID: 16021497
-
Efficacy of sub-Tenon's capsule injection of triamcinolone acetonide for refractory diabetic macular edema after vitrectomy.J Med Invest. 2008 Aug;55(3-4):279-82. doi: 10.2152/jmi.55.279. J Med Invest. 2008. PMID: 18797143
-
Review on the Use of Difluprednate in Inflammatory Eye Disorders: The Topical Steroid That Goes the Distance.Ocul Immunol Inflamm. 2025 May;33(4):670-682. doi: 10.1080/09273948.2024.2423869. Epub 2024 Nov 6. Ocul Immunol Inflamm. 2025. PMID: 39504538 Review.
Cited by
-
Risk of Elevated Intraocular Pressure With Difluprednate in Patients With Non-Infectious Uveitis.Am J Ophthalmol. 2022 Aug;240:232-238. doi: 10.1016/j.ajo.2022.03.026. Epub 2022 Apr 2. Am J Ophthalmol. 2022. PMID: 35381204 Free PMC article.
-
Topical difluprednate for the treatment of Harada's disease.Clin Ophthalmol. 2015 Jan 21;9:157-67. doi: 10.2147/OPTH.S72955. eCollection 2015. Clin Ophthalmol. 2015. PMID: 25653498 Free PMC article.
-
Retinal Diseases: The Next Frontier in Pharmacodelivery.Pharmaceutics. 2022 Apr 21;14(5):904. doi: 10.3390/pharmaceutics14050904. Pharmaceutics. 2022. PMID: 35631490 Free PMC article. Review.
-
Diabetic Macular Edema: Current Understanding, Molecular Mechanisms and Therapeutic Implications.Cells. 2022 Oct 25;11(21):3362. doi: 10.3390/cells11213362. Cells. 2022. PMID: 36359761 Free PMC article. Review.
-
Cytomegalovirus retinitis after treatment with topical difluprednate in an aphakic eye of an immunocompetent patient.Am J Ophthalmol Case Rep. 2019 Sep 10;16:100552. doi: 10.1016/j.ajoc.2019.100552. eCollection 2019 Dec. Am J Ophthalmol Case Rep. 2019. PMID: 31650081 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous